Pyridorin in Diabetic Nephropathy

Phase 3

Terminated

• Conditions: Diabetic Nephropathy; Diabetic Kidney Disease
• Interventions: Drug: Pyridorin; Drug: Placebo

• Registration Number: NCT02156843
• Lead Sponsor: NephroGenex, Inc.

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of oral Pyridorin 300 mg BID in reducing the rate of progression of nephropathy due to type 2 diabetes mellitus.

Detailed Description

This is a randomized, double-blind, placebo-controlled, multi-center Phase 3 study to evaluate the safety and efficacy of Pyridorin 300 mg BID (twice daily, every 12 hours) in subjects with nephropathy due to type 2 diabetes mellitus. In this study, nephropathy is defined as a Serum Creatinine (SCr) \>= 1.3 (≥1.25) mg/dL (111 umol/L) for female and \>=1.5 (≥1.45) mg/dL (128 umol/L) for male subjects and a 24-hour urine collection protein/creatinine ration (PCR) \>=1200 mg/g (136 mg/mmol), and if applicable for PS Phase, at Visit 1S or 1.1S a 24-urine collection PCR ≥600 mg/g (68 mg/mmol). Subjects must have a baseline SCr \< 3.0 mg/dL (265 umol/L) and must be on previously established standard of care at screening.

Study Timeline

• Study First Submitted: 2014-05-28
• Study Start: 2014-06
• Study First Submitted QC: 2014-06-03
• Study First Posted: 2014-06-05
• Status Verified: 2016-03
• Last Update Submitted: 2016-03-08
• Last Update Posted: 2016-03-09
• Primary Completion: 2017-12
• Study Completion: 2018-03

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 328

Inclusion Criteria

Patients meeting all of the following criteria will be eligible to participate in the study:

1. Patients who have given voluntary written informed consent to participate in this study prior to conducting Screening (Visit 1) procedures;

2. Patients 18 years of age or older with a diagnosis of type 2 diabetes;

3. Women of childbearing potential (WOCBP) who agree to use appropriate birth control (double-barrier methods, hormonal contraceptives, or intrauterine device) for the duration of the study (women of childbearing potential is defined as all women who are not surgically sterile or are not at least 1 year post menopausal). All women of childbearing potential must have a negative serum pregnancy test at Visit 1;

4. All men (unless surgically sterile, as defined below) who have sexual intercourse with a WOCBP must agree and commit to use a highly effective method of contraception for the duration of the study (defined as the time of the signing of the informed consent form through the conclusion of patient participation). Highly effective methods of contraception include:

   i. Male subjects agreeing that they and their female spouse/partners will use adequate contraception (2 forms of birth control, one of which must be barrier method) or be of non-childbearing potential.

   ii. To be considered surgically sterilized, a male partner must have had a vasectomy at least 24 weeks before Visit 1;

5. At Visit 1, patients must have a history of overt diabetic nephropathy, as defined by the following:

   • A SCr measurement ≥1.3 (≥1.25)mg/dL (111 µmol/L) for females or ≥1.5 (≥1.45) mg/dL (128 µmol/L) for males;
   • At Visit 1 or 1.1 24-hour urine collection PCR >1200 mg/g (130 mg/µmol) and, if applicable for PS phase, at Visit 1S or 1.1S a 24-urine collection PCR >600 mg/g (67 mg/µmol)
   • For eligibility determination, laboratory reported values of PCR will be rounded up to 2 significant digits (e.g. ≥1150 mg/g to 1200 mg/g; ≥595 mg/g to 600 mg/g),

6. Patients must have a SCr measurement <3.0 mg/dL (265 µmol/L);

7. Patients must have an eGFR of ≥20 mL/min/1.73m2, using the 4-variable Modification of Diet in Renal Disease equation in which eGFR = 175 x (SCr(mg/dL))-1.154 x (Age(years))-0.203 x (0.742 if female) x (1.212 if African American);

8. Patient must have a second screening SCr measurement at Visit 1.1 or 1.1S taken 1 week (± 2 days) after screening (Visit 1 or 1S). The value of the second screening SCr measurement must be <3.0 mg/dL (265 µmol/L) for both genders and within 25% of the first screening measurement;

9. Patients must be taking a single ACE-I or ARB at a constant dose for at least 26 weeks prior to Visit 1, where the dose of the ACE-I or the ARB is considered appropriate for that patient (can be zero to max dose approved by the FDA) and it is anticipated that the same dose can and will be maintained throughout the course of the study;

10. Patients taking any blood pressure medications in addition to an ACE-I or ARB, including diuretics, must be on a stable dose for 13 weeks prior to Visit 1 (and Visit 1S if applicable) with a seated blood pressure of ≤ 150/90 mmHg;

11. Patients not taking any blood pressure medications, including diuretics, other than an ACE-I or ARB must have a seated blood pressure ≤ 150/90 mmHg at Visit 1 (and Visit 1S if applicable) and a seated blood pressure considered appropriate for the patient and one that can be sustained throughout the study.

Exclusion Criteria

Patients are excluded from participation in the study if any of the following criteria apply

1. Patients with type 1 diabetes or MODY (a monogenic form of diabetes);
2. Patients with a diagnosis of chronic kidney disease other than diabetic renal disease with or without hypertensive renal disease
3. Patients receiving a renin inhibitor or an aldosterone antagonist or a combination of an ACE-I and an ARB within 26 weeks of Visit 1
4. Patients with a history of solid organ transplantation
5. Patients with a history of myocardial infarction, coronary re-vascularization procedures (including percutaneous transluminal coronary angioplasty), stroke, or transient ischemic attack within 30 days prior to Visit 1
6. Patients with a diagnosis of New York Heart Association Class III or IV congestive heart failure at any time
7. Patients with a history of being treated for neoplastic disease (except basal or squamous cell carcinoma of the skin) within 5 years prior to Visit 1
8. Patients with any history of dialysis within 2 years prior to Visit 1
9. Patients in whom dialysis or renal transplantation is anticipated by their physician within 1 year after Visit 1
10. Patients who used SCr-altering drugs within 30 days prior to Visit 1
11. Patients who require systemic immunosuppression therapy for >2 weeks (except for inhalant steroids)
12. Patients with clinically significant liver disease or transaminase (alanine aminotransferase and aspartate aminotransferase) levels >2.5 × the upper limit of normal (ULN) measured at Visit 1.1 or Visit 1.1S
13. Patients with bilirubin levels >1.5 × ULN measured at Visit 1.1 or Visit 1.1S
14. Patients with a history of allergic or other adverse response to vitamin B preparations
15. Patients who require >50 mg of vitamin B6 daily
16. Patients who have an active history of dysphagia or swallowing disorders
17. Patients with a history of hypersensitivity to Pyridorin or any of the excipients (non-active ingredients) in the Pyridorin formulation
18. Patients who have taken pyridoxamine or any other investigational drug within 30 days prior to Visit 1, or have participated in a previous Pyridorin study or another interventional clinical study within 30 days prior to Visit 1
19. Patients with an active history of drug or alcohol abuse
20. Patients unlikely to comply with the study protocol (eg, an inability and unwillingness to participate in adequate training, an uncooperative attitude, inability to return for follow-up visits, or unlikelihood of completing the study)
21. Women who are lactating, pregnant, or intend to become pregnant during the course of the study
22. Persons employed with the sponsor, CRO, or one of the study investigative sites must be excluded from participation, even if they are not involved directly in the conduct of the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pyridorin	Pyridorin	Pyridorin (pyridoxamine dihydrochloride) 300 mg oral BID (twice daily, every 12 hours) Capsule
Placebo	Placebo	Placebo Oral Capsule taken BID (twice daily, every 12 hours)

Primary Outcome Measures

Name	Time	Method
Time to composite endpoint of >=50% SCr increase from baseline or ESRD	Approximately 45 Months	Time to the composite endpoint consisting of the earliest event amongst a SCr increase of 50% from baseline that occurs during follow-up; or End Stage Renal Disease. ESRD is defined as the initiation of permanent dialysis, receiving a kidney transplant, or a SCr value \>= 6.0 mg/dL (530 umol/L) with a second SCr confirmation value \>=6.0 mg/dL (530 umol/L) obtained 4-6 weeks later. A confirmation of SCr value for subjects with ESRD and initiation of permanent dialysis or kidney transplant will not be collected.

Secondary Outcome Measures

Name	Time	Method
Time to the composite endpoint >=100% SCr increase or ESRD	Approximately 45 Months	A SCr increase of \>=100% that occurs during follow-up; or ESRD

Trial Locations

Locations (137)

CSG Investigational Site (#160); 🇺🇸 Los Angeles, California, United States

CSG Investigational Site (#143); 🇺🇸 Riverside, California, United States

CSG Investigational Site (#113); 🇺🇸 Chicago, Illinois, United States

CSG Investigational Site (#117); 🇺🇸 Boston, Massachusetts, United States

CSG Investigational Site (#141); 🇺🇸 Las Vegas, Nevada, United States

CSG Investigational Site (#108); 🇺🇸 Asheville, North Carolina, United States

CSG Investigational Site (#106); 🇺🇸 Columbus, Ohio, United States

CSG Investigational Site (#151); 🇺🇸 Cleveland, Ohio, United States

CSG Investigational Site (#149); 🇺🇸 Pittsburgh, Pennsylvania, United States

CSG Investigational Site (#139); 🇺🇸 Houston, Texas, United States

CSG Investigational Site (#123); 🇺🇸 Cleveland, Ohio, United States

CSG Investigational Site (#101); 🇺🇸 Philadelphia, Pennsylvania, United States

CSG Investigational Site (#137); 🇺🇸 Fairfax, Virginia, United States

CSG Investigational Site (#103); 🇺🇸 Fairfax, Virginia, United States

CSG Investigational Site (#205); 🇦🇺 Camperdown, New South Wales, Australia

CSG Investigational Site (#206); 🇦🇺 Liverpool, New South Wales, Australia

CSG Investigational Site (#301); 🇮🇱 Zerifin, Israel

CSG Investigational Site (#605); 🇪🇸 Barcelona, Spain

CSG Investigational Site (#119); 🇺🇸 Dallas, Texas, United States

CSG Investigative Site (#204); 🇦🇺 Adelaide, South Australia, Australia

CSG Investigational Site (#207); 🇦🇺 Footscray, Victoria, Australia

CSG Investigational Site (# 850); 🇲🇺 Phoenix, Mauritius

CSG Investigational Site (#655); 🇵🇱 Chojnice, Poland

CSG Investigational Site (#657); 🇵🇱 Nowy Sacz, Poland

CSG Investigational Site (#112); 🇵🇷 Rio Piedras, Puerto Rico

CSG Investigational Site (#604); 🇪🇸 Barcelona, Spain

CSG Investigational Site (#312); 🇮🇱 Petah Tikva, Israel

CSG Investigational Site (#311); 🇮🇱 Rishon Le-Zion, Israel

CSG Investigational Site (#800); 🇫🇷 Boulogne Sur Mer, France

CSG Investigational Site (#305); 🇮🇱 Tel Aviv, Israel

CSG Investigational Site (#315); 🇮🇱 Poriya, Israel

CSG Investigational Site (#300); 🇮🇱 Haifa, Israel

CSG Investigational Site (#110); 🇵🇷 San Juan, Puerto Rico

CSG Investigational Site (#601); 🇪🇸 San Sebastian de los Reyes, Madrid, Spain

CSG Investigational Site (#600); 🇪🇸 Girona, Spain

CSG Investigational Site (#603); 🇪🇸 Barcelona, Spain

CSG Investigational Site (#150); 🇺🇸 Phoenix, Arizona, United States

CSG Investigational Site (#111); 🇺🇸 Detroit, Michigan, United States

CSG Investigational Site (#124); 🇺🇸 Cincinnati, Ohio, United States

CSG Investigational Site (#132); 🇺🇸 Salt Lake City, Utah, United States

CSG Investigational Site (#105); 🇺🇸 Nashville, Tennessee, United States

CSG Investigational Site (#157); 🇺🇸 Birmingham, Alabama, United States

CSG Investigational Site (#310); 🇮🇱 Tel Hasomer, Israel

CSG Investigational Site (#303); 🇮🇱 Tel Aviv, Israel

CSG Investigational Site (#602); 🇪🇸 Valencia, Spain

CSG Investigational Site (# 607); 🇪🇸 Lleida, Spain

CSG Investigational Site (#130); 🇺🇸 Phoenix, Arizona, United States

CSG Investigational Site (#145); 🇺🇸 Prescott, Arizona, United States

CSG Investigational Site (#142); 🇺🇸 Tucson, Arizona, United States

CSG Investigational Site (#120); 🇺🇸 Westminster, Colorado, United States

CSG Investigational Site (#153); 🇺🇸 Arvada, Colorado, United States

CSG Investigational Site (#159); 🇺🇸 Roseville, California, United States

CSG Investigational Site (#158); 🇺🇸 Waterbury, Connecticut, United States

CSG Investigational Site (#102); 🇺🇸 Michigan City, Indiana, United States

CSG Investigational Site (#156); 🇺🇸 Columbus, Georgia, United States

CSG Investigational Site (#114); 🇺🇸 Springfield, Massachusetts, United States

CSG Investigational Site (#115); 🇺🇸 New Orleans, Louisiana, United States

CSG Investigational Site (#147); 🇺🇸 Greenbelt, Maryland, United States

CSG Investigational Site (#134); 🇺🇸 Pontiac, Michigan, United States

CSG Investigational Site (#128); 🇺🇸 Buffalo, New York, United States

CSG Investigational Site (#154); 🇺🇸 West Nyack, New York, United States

CSG Investigational Site (#136); 🇺🇸 Northport, New York, United States

CSG Investigational Site (#125); 🇺🇸 Durham, North Carolina, United States

CSG Investigational Site (#116); 🇺🇸 Charlotte, North Carolina, United States

CSG Investigational Site (#148); 🇺🇸 Parma Heights, Ohio, United States

CSG Investigational Site (#131); 🇺🇸 Chattanooga, Tennessee, United States

CSG Investigational Site (#146); 🇺🇸 Providence, Rhode Island, United States

CSG Investigational Site (#133); 🇺🇸 Houston, Texas, United States

CSG Investigational Site (#109); 🇺🇸 Midland, Texas, United States

CSG Investigational Site (#107); 🇺🇸 Burlington, Vermont, United States

CSG Investigational Site (#129); 🇺🇸 Charlottesville, Virginia, United States

CSG Investigational Site (#104); 🇺🇸 Hampton, Virginia, United States

CSG Investigational Site (#121); 🇺🇸 Spokane, Washington, United States

CSG Investigational Site (#144); 🇺🇸 Richmond, Virginia, United States

CSG Investigational Site (#201); 🇦🇺 Gosford, New South Wales, Australia

CSG Investigational Site (#208); 🇦🇺 St. Leonards, New South Wales, Australia

CSG Investigational Site (#200); 🇦🇺 Reservoir, Victoria, Australia

CSG Investigational Site (#209); 🇦🇺 Parkville, Australia

CSG Investigational Site (#202); 🇦🇺 Richmond, Victoria, Australia

CSG Investigational Site (#757); 🇧🇬 Plovdiv, Bulgaria

CSG Investigational Site (#510); 🇭🇺 Kisvarda, Hungary

CSG Investigational Site (#707); 🇩🇪 Herzberg, Germany

CSG Investigational Site (# 750); 🇧🇬 Sofia, Bulgaria

CSG Investigational Site (# 755); 🇧🇬 Sofia, Bulgaria

CSG Investigational Site (#752); 🇧🇬 Sofia, Bulgaria

CSG Investigational Site (#751); 🇧🇬 Sofia, Bulgaria

CSG Investigational Site (#754); 🇧🇬 Stara Zagora, Bulgaria

CSG Investigational Site (#802); 🇫🇷 Paris, Cedex, France

CSG Investigational Site (#801); 🇫🇷 Grenoble, Cedex, France

CSG Investigational Site (#806); 🇫🇷 Montpellier, France

CSG Investigational Site (#804); 🇫🇷 Rhone, France

CSG Investigational Site (#803); 🇫🇷 Colmar, France

CSG Investigational Site (#709); 🇩🇪 Aschaffenburg, Germany

CSG Investigational Site (#706); 🇩🇪 Elsterwerda, Germany

CSG Investigational Site (#805); 🇫🇷 Valenciennes, France

CSG Investigational Site (#703); 🇩🇪 Heidelberg, Germany

CSG Investigative Site (#702); 🇩🇪 Berlin, Germany

CSG Investigational Site (#708); 🇩🇪 Mainz, Germany

CSG Investigational Site (#400); 🇭🇰 Hong Kong, Hong Kong

CSG Investigational Site (#701); 🇩🇪 Hoyerswerda, Germany

CSG Investigational Site (#700); 🇩🇪 Munchen, Germany

CSG Investigational Site (#505); 🇭🇺 Budapest, Hungary

CSG Investigational Site (#508); 🇭🇺 Gyula, Hungary

CSG Investigational Site (#502); 🇭🇺 Hatvan, Hungary

CSG Investigational Site (#506); 🇭🇺 Pecs, Hungary

CSG Investigational Site (#504); 🇭🇺 Kaposvar, Hungary

CSG Investigational Site (#514); 🇭🇺 Szekesfehervar, Hungary

CSG Investigational Site (#503); 🇭🇺 Zalaegerszeg, Hungary

CSG Investigational Site (#307); 🇮🇱 Ashkelon, Israel

CSG Investigational Site (#308); 🇮🇱 Safed, Zefad, Israel

CSG Investigational Site (#313); 🇮🇱 Beer Sheva, Israel

CSG Investigational Site (#306); 🇮🇱 Jerusalem, Israel

CSG Investigational Site (#304); 🇮🇱 Holon, Israel

CSG Investigational Site (#309); 🇮🇱 Kfar Saba, Israel

CSG Investigational Site (#314); 🇮🇱 Jerusalem, Israel

CSG Investigational Site (#302); 🇮🇱 Nahariya, Israel

CSG Investigational Site (#651); 🇵🇱 Bydgoszcz, Poland

CSG Investigational Site (#653); 🇵🇱 Kielce, Poland

CSG Investigational Site (#656); 🇵🇱 Poznan, Poland

CSG Investigational Site (#135); 🇵🇷 Toa Baja, Puerto Rico

CSG Investigational Site (#606); 🇪🇸 Barcelona, Spain

CSG Investigational Site (#155); 🇺🇸 New Bern, North Carolina, United States

CSG Investigational Site (# 756); 🇧🇬 Sofia, Bulgaria

CSG Investigational Site (#500); 🇭🇺 Szikszo, Hungary

CSG Investigational Site (#753); 🇧🇬 Sofia, Bulgaria

CSG Investigational Site (#652); 🇵🇱 Poznan, Poland

CSG Investigational Site (#513); 🇭🇺 Budapest, Hungary

CSG Investigational Site (#402); 🇭🇰 Kwai Chung, Hong Kong

CSG Investigational Site (#501); 🇭🇺 Balatonfuered, Hungary

CSG Investigational Site (#507); 🇭🇺 Debrecen, Hungary

CSG Investigational Site (#509); 🇭🇺 Budapest, Hungary

CSG Investigational Site (#162); 🇺🇸 Kansas City, Missouri, United States

CSG Investigational Site (#152); 🇺🇸 Kansas City, Missouri, United States

CSG Investigational Site (#118); 🇺🇸 Aurora, Colorado, United States

CSG Investigational Site (#127); 🇺🇸 Winston-Salem, North Carolina, United States

CSG Investigational Site (#122); 🇺🇸 Milwaukee, Wisconsin, United States

CSG Investigational Site (#401); 🇭🇰 Sha Tin, Hong Kong